NORTH HOLLYWOOD, Calif.--(BUSINESS WIRE)--The International Myeloma Foundation (IMF) today noted REVLIMID® was granted the Prix Galien USA 2008 Award for Special Therapeutic Development, and congratulated Celgene and all of the researchers, patients and physicians who helped in the drug’s development. REVLIMID is an oral cancer drug for the treatment of multiple myeloma. The Prix Galien Award, considered to be the highest accolade for pharmaceutical research and development, was presented during a ceremony in New York City on September 24.
